ARTL Stock — Artelo Biosciences Inc

Artelo Biosciences Inc (ARTL)

Updated October 16, 2026.

ARTL is a Stock. Total return is -100.0% over the past 8.9 years, 339.9 points behind SPY at 239.9%.

Artelo Biosciences is a clinical-stage biopharmaceutical company developing therapeutics that target lipid-signaling pathways, with a pipeline including candidates for cancer-related anorexia, anxiety, depression, PTSD, epilepsy, insomnia, and various pain and neuropathy conditions. The company does not currently distribute dividends. Artelo appeals to investors seeking exposure to early-stage drug development with higher risk and growth orientation rather than current income.

ARTL performance versus SPY

Price and return data through 2026-10-16.

Total return is -100.0% over the past 8.9 years, 339.9 points behind SPY at 239.9%. Over the past year its total return — price change plus distributions reinvested — is -97.5%. Its deepest 1-year drawdown was 97.6%.

ARTL key facts

Asset type

Stock

Asset class

Equity

Inception date

11/14/2017

Distribution frequency

None

Last close

$2.70 (as of 2026-10-16)

Market cap

$1,478,990

Average volume

12300.0

Payment date

06/21/2019

Beta

-0.074

Payout ratio

0.0%

EPS

$-136.26

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ARTL risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 97.6%.

Who may consider ARTL — and who may not

It is a weaker fit for investors who need monthly cash flow (ARTL does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on ARTL

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions